EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta‐analysis

Giuseppe Indolfi iD, Philippa Easterbrook iD, Sabrina Giometto iD, Farihah Malik iD, Roger Chou iD, Ersilia Lucenteforte iD

Liver International · 2024-03 · 44 (3) · 663-681

DOI: 10.1111/liv.15827 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Liver International, online erschienen am 31.01.2024. Verfasst von Giuseppe Indolfi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department Neurofarba, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Sustained Virologic Response, Pyrrolidines. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims We evaluated the effectiveness and safety of pan‐genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/daclatasvir (SOF/DCV) and other direct‐acting antivirals (DAA) regimens for the treatment of hepatitis C virus (HCV)‐infected adolescents (12–18 years), older children (6–11 years), and young children (3–5 years). The purpose of this systematic review and meta‐analysis was to inform the World Health Organization (WHO) guidelines.

Methods

We included clinical trials and observational studies published up to August 11, 2021, that evaluated DAA regimens in HCV‐infected adolescents, older children, and young children. We searched MEDLINE, EMBASE, and CENTRAL databases and key conference abstracts. Sustained virological response 12 weeks after the end of treatment (SVR12), adverse events (AEs), and treatment discontinuation were the outcomes evaluated. Risk of bias was assessed using a modified version of the ROBINS‐I tool. Data were pooled using random‐effects models, and certainty of the evidence was assessed using the GRADE approach.

Results

A total of 49 studies including 1882 adolescents, 436 older children, and 166 young children were considered. The SVR12 was 100% (95% Confidence Interval: 96–100), 96% (90–100), and 96% (83–100) for GLE/PIB in adolescents, older, and young children, respectively; 95% (90–99), 93% (86–98), and 83% (70–93), for SOF/VEL, respectively; and 100% (97–100) and 100% (94–100) for SOF/DCV in adolescent and older children, respectively. There was a clear trend towards a higher rate of any reported AE from adolescents (50%), older children (53%), to young children (72%). Serious AEs and treatment discontinuations were uncommon in adolescents and older children (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicAntiviral AgentsSustained Virologic ResponsePyrrolidinesHumansChildAdolescentHepacivirusBenzimidazolesChild, PreschoolCarbamatesSulfonamidesSofosbuvirHeterocyclic Compounds, 4 or More RingsDrug CombinationsValineImidazolesCyclopropanesQuinoxalines

Stichwörter der Autor:innen

HCVSVR12childrendirect-acting antiviralsmeta-analysissystematic review

Substanzen

Antiviral AgentsPyrrolidinesBenzimidazolesCarbamatesSulfonamidesSofosbuvirHeterocyclic Compounds, 4 or More RingsDrug Combinationsglecaprevir and pibrentasvirValine

Autor:innen und Institutionen

  • Department Neurofarba, University of Florence, Florence, Italy.
  • Paediatric and Liver Unit, Meyer Children's Hospital IRCCS, Firenze, Italy.
  • Global HIV, Hepatitis and STI Programmes, World Health Organization Headquarters, Geneva, Switzerland.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Departments of Medicine, and Medical Informatics & Clinical Epidemiology, Oregon Health Sciences University, Portland, Oregon, USA.

ORCID-Profile: Giuseppe Indolfi, Philippa Easterbrook, Sabrina Giometto, Farihah Malik, Roger Chou, Ersilia Lucenteforte

Förderung

  • World Health Organization

Zitieren

APA

Indolfi, G., Easterbrook, P., Giometto, S., Malik, F., Chou, R., & Lucenteforte, E. (2024). Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta‐analysis. Liver International, 44(3), 663-681. https://doi.org/10.1111/liv.15827

Vancouver

Indolfi G, Easterbrook P, Giometto S, Malik F, Chou R, Lucenteforte E. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta‐analysis. Liver International. 2024;44(3):663-681. doi:10.1111/liv.15827

BibTeX
@article{Indolfi2024,
  author = {Indolfi, Giuseppe and Easterbrook, Philippa and Giometto, Sabrina and Malik, Farihah and Chou, Roger and Lucenteforte, Ersilia},
  title = {Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta‐analysis},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {3},
  pages = {663--681},
  doi = {10.1111/liv.15827}
}
Kostenlos starten →